Dapagliflozin

A Novel Sodium-glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Niren K. Shah, Pharm.D.; Wasim E. Deeb, M.D.; Rushab Choksi, Pharm.D.; Benjamin J. Epstein, Pharm.D.

Disclosures

Pharmacotherapy. 2012;32(1):80-94. 

In This Article

Literature Search

We conducted a comprehensive literature search of the MEDLINE database to identify all relevant studies published in English between 1959 and February 2011. The following medical subject heading terms and key words were used: dapagliflozin, SGLT2 inhibition, BMS-512148, type 2 diabetes mellitus, oral antidiabetic agents, hyperglycemia, and renal glucose reabsorption. All pertinent reviews and research reports were evaluated, and studies performed in both humans and animals were included. Other articles with information relevant to SGLT2 inhibition were also included. Because of the limited information available, abstracts and scientific presentations of phase III clinical studies not yet published were incorporated for completeness.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....